Cosmax joins Harvard-affiliated hospital network to pursue anti-aging, metabolic research
Cosmax Group is moving beyond cosmetics into medical and biotechnology research through an expanded partnership with a Harvard-affiliated hospital network, targeting potential treatments and health products for aging, weight management and metabolic health. The Korean cosmetics manufacturer said Tuesday it signed an agreement Oct. 13 in Boston with Mass General Brigham (MGB) to launch the second…
Cosmax Group, the Korean cosmetics manufacturer, is expanding its focus from skincare to medical and biotechnology research by joining a partnership with a Harvard-affiliated hospital network. The agreement, signed on October 13 in Boston, aims to explore treatments and health products related to aging, weight management, and metabolic health.
This partnership, known as the VIVA project, is set to begin its second phase from 2026 to 2029. During this period, Cosmax and Mass General Brigham (MGB) will broaden their research beyond cosmetic ingredients to include functional ingredients for health supplements and potential drug candidates.
The collaboration builds upon research conducted from 2024 to 2026, which identified a substance derived from certain microorganisms that alleviated symptoms of atopic dermatitis and improved skin barrier function. This discovery, published in the international journal Allergy, has led Cosmax to file a Korean patent application related to the microbial technology.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
